Pyoderma Gangrenosum
32
2
2
11
Key Insights
Highlights
Success Rate
58% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
25.0%
8 terminated out of 32 trials
57.9%
-28.6% vs benchmark
28%
9 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (32)
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Spesolimab in Pyoderma Gangrenosum
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
Deucravacitinib in PG
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum